Decision support for organ offers in liver transplantation

Michael L. Volk, Nathan Goodrich, Jennifer C. Lai, Christopher Sonnenday, Kerby Shedden – 16 March 2015 – Organ offers in liver transplantation are high‐risk medical decisions with a low certainty of whether a better liver offer will come along before death. We hypothesized that decision support could improve the decision to accept or decline. With data from the Scientific Registry of Transplant Recipients, survival models were constructed for 42,857 waiting‐list patients and 28,653 posttransplant patients from 2002 to 2008.

Patterns and predictors of sexual function after liver donation: The adult‐to‐adult living donor liver transplantation cohort study

Andrea F. DiMartini, Mary Amanda Dew, Zeeshan Butt, Mary Ann Simpson, Daniela P. Ladner, Abigail R. Smith, Peg Hill‐Callahan, Brenda W. Gillespie – 16 March 2015 – Although sexual functioning is an important facet of a living donor's quality of life, it has not received an extensive evaluation in this population. Using data from the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study, we examined donor sexual functioning across the donation process from the predonation evaluation to 3 months and 1 year after donation.

Reply

Constantine J. Karvellas, R. Todd Stravitz, Holly Battenhouse, William M. Lee, Michael L. Schilsky, for the US Acute Liver Failure Study Group – 16 March 2015

Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy: Repeat hepatectomy versus salvage living donor liver transplantation

Yo‐Ichi Yamashita, Yoshihiro Yoshida, Takeshi Kurihara, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara – 13 March 2015 – The aims of this study were to evaluate the efficacy of repeat hepatectomy (Hx) and salvage living donor liver transplantation (LDLT) for recurrent hepatocellular carcinoma (HCC). A retrospective cohort study was performed to analyze the surgical results of repeat Hx and salvage LDLT for patients with recurrent HCC within the Milan criteria from 1989 to 2012.

Cilostazol improves hepatic blood perfusion, microcirculation, and liver regeneration after major hepatectomy in rats

Maximilian von Heesen, Stefan Dold, Simon Müller, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger, Mohammed R. Moussavian – 13 March 2015 – Major hepatectomy or small‐for‐size liver transplantation may result in postoperative liver failure. So far, no treatment is available to improve liver regeneration. Herein, we studied whether cilostazol, a selective phosphodiesterase III inhibitor, is capable of improving liver regeneration after major hepatectomy.

Higher Mortality in registrants with sudden model for end‐stage liver disease increase: Disadvantaged by the current allocation policy

Allan B. Massie, Xun Luo, Jennifer L. Alejo, Anna K. Poon, Andrew M. Cameron, Dorry L. Segev – 12 March 2015 – Liver allocation is based on current Model for End‐Stage Liver Disease (MELD) scores, with priority in the case of a tie being given to those waiting the longest with a given MELD score. We hypothesized that this priority might not reflect risk: registrants whose MELD score has recently increased receive lower priority but might have higher wait‐list mortality. We studied wait‐list and posttransplant mortality in 69,643 adult registrants from 2002 to 2013.

Subscribe to